BACKGROUND: Obesity increases the risk for renal cell carcinoma (RCC). However, it has only recently been identified as an independent positive prognostic factor for localized RCC. OBJECTIVE: To determine whether obesity influences long-term prognosis in metastatic RCC patients receiving vascular endothelial growth factor-targeted therapy. DESIGN, SETTING, AND PARTICIPANTS: In 116 patients with metastatic RCC who received antiangiogenic agents (sunitinib, sorafenib, axitinib, bevacizumab) in 2005-2010, we evaluated whether body mass index (BMI), a body surface area (BSA) above the European average, the visceral fat area (VFA), or s.c. fat area (SFA) were of predictive relevance. MEASUREMENTS: BMI was categorized based on current World Health Organization definitions. BSA was stratified according to the European average for men (1.98 m(2)) and women (1.74 m(2)). VFA and SFA were dichotomized using the median of the observed distribution as the cutoff. The primary endpoints of this study were time to progression and overall survival time. RESULTS AND LIMITATIONS: The whole population had median progression-free and overall survival times of 8.3 months and 20.5 months, respectively. In contrast to BMI and BSA, higher than average VFA and SFA levels were significant predictors of longer progression-free and overall survival times. The major limitations of this study are its retrospective design and its heterogeneous patient population. CONCLUSION: This is the first study to identify high VFA and SFA levels as positive predictive biomarkers for patients who receive first-line antiangiogenic agents for metastatic RCC.
BACKGROUND:Obesity increases the risk for renal cell carcinoma (RCC). However, it has only recently been identified as an independent positive prognostic factor for localized RCC. OBJECTIVE: To determine whether obesity influences long-term prognosis in metastatic RCCpatients receiving vascular endothelial growth factor-targeted therapy. DESIGN, SETTING, AND PARTICIPANTS: In 116 patients with metastatic RCC who received antiangiogenic agents (sunitinib, sorafenib, axitinib, bevacizumab) in 2005-2010, we evaluated whether body mass index (BMI), a body surface area (BSA) above the European average, the visceral fat area (VFA), or s.c. fat area (SFA) were of predictive relevance. MEASUREMENTS: BMI was categorized based on current World Health Organization definitions. BSA was stratified according to the European average for men (1.98 m(2)) and women (1.74 m(2)). VFA and SFA were dichotomized using the median of the observed distribution as the cutoff. The primary endpoints of this study were time to progression and overall survival time. RESULTS AND LIMITATIONS: The whole population had median progression-free and overall survival times of 8.3 months and 20.5 months, respectively. In contrast to BMI and BSA, higher than average VFA and SFA levels were significant predictors of longer progression-free and overall survival times. The major limitations of this study are its retrospective design and its heterogeneous patient population. CONCLUSION: This is the first study to identify high VFA and SFA levels as positive predictive biomarkers for patients who receive first-line antiangiogenic agents for metastatic RCC.
Authors: T Yoshizumi; T Nakamura; M Yamane; A H Islam; M Menju; K Yamasaki; T Arai; K Kotani; T Funahashi; S Yamashita; Y Matsuzawa Journal: Radiology Date: 1999-04 Impact factor: 11.105
Authors: W H Chow; J K McLaughlin; J S Mandel; S Wacholder; S Niwa; J F Fraumeni Journal: Cancer Epidemiol Biomarkers Prev Date: 1996-01 Impact factor: 4.254
Authors: Andres Jan Schrader; Julia Rustemeier; Jan Christoph Rustemeier; Nina Timmesfeld; Zoltan Varga; Axel Hegele; Peter Jochen Olbert; Rainer Hofmann Journal: J Cancer Res Clin Oncol Date: 2009-06-20 Impact factor: 4.553
Authors: Yunzhi Wang; Theresa Thai; Kathleen Moore; Kai Ding; Scott McMeekin; Hong Liu; Bin Zheng Journal: Oncol Lett Date: 2016-05-31 Impact factor: 2.967
Authors: Laurence Albiges; A Ari Hakimi; Wanling Xie; Rana R McKay; Ronit Simantov; Xun Lin; Jae-Lyun Lee; Brian I Rini; Sandy Srinivas; Georg A Bjarnason; Scott Ernst; Lori A Wood; Ulka N Vaishamayan; Sun-Young Rha; Neeraj Agarwal; Takeshi Yuasa; Sumanta K Pal; Aristotelis Bamias; Emily C Zabor; Anders J Skanderup; Helena Furberg; Andre P Fay; Guillermo de Velasco; Mark A Preston; Kathryn M Wilson; Eunyoung Cho; David F McDermott; Sabina Signoretti; Daniel Y C Heng; Toni K Choueiri Journal: J Clin Oncol Date: 2016-10-20 Impact factor: 44.544
Authors: Roy Mano; A Ari Hakimi; Emily C Zabor; Marta A Bury; Olivio F Donati; Christoph A Karlo; Wassim M Bazzi; Helena Furberg; Paul Russo Journal: Can Urol Assoc J Date: 2014-09 Impact factor: 1.862
Authors: K N Slaughter Wade; M F Brady; T Thai; Y Wang; B Zheng; R Salani; K S Tewari; H J Gray; J N Bakkum-Gamez; R A Burger; K N Moore; M A Bookman Journal: Gynecol Oncol Date: 2019-08-10 Impact factor: 5.482
Authors: Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain Journal: Sci Transl Med Date: 2018-03-14 Impact factor: 17.956